NASDAQ$TLPH
AcelRx Pharmaceuticals Inc · Q2 2021 earnings
Q2 2021 earnings · · Investor relations
Briefing
AcelRx reported second quarter 2021 financial results.
AcelRx Pharmaceuticals reported a net revenue of $0.4 million and a net loss of $9.9 million, or $0.08 per share for the second quarter of 2021. The company's cash and short-term investments balance was $55.3 million as of June 30, 2021. DSUVIA sales increased by 117% compared to Q1 2021.
- DSUVIA sales increased by 117% compared to Q1 2021.
- Entered into an agreement with Laboratoire Aguettant for DZUVEO commercialization in Europe, with potential for $55 million in milestone payments.
- USAMMDA publicly communicated their support of DSUVIA for battlefield pain management.
- Reached agreement with the FDA on corrective actions regarding a warning letter about DSUVIA promotional materials.
Headline financials
Revenue & EPS history
AcelRx · Revenue · Quarterly
$443K
Forward guidance
AcelRx is on track to exceed its guidance of 615 approvals by year end 2021 and plans to file New Drug Applications for two innovative pre-filled syringe product candidates within 12 months.
Tailwinds
- Continued sales momentum with DSUVIA.
- Real-world data becoming more widely disseminated.
- Elective surgery restrictions easing.
- Commitment to investigator-initiated trials.
- Business development remains a key priority.
Headwinds
- Uncertainties inherent in investigator-initiated studies.
- Possible material differences in actual results.
- Risks and uncertainties described in AcelRx’s reports filed with the SEC.
- Do not place undue reliance on any forward-looking statements.
- Financial information is in summary form only.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q2 2021
-2.7%
Avg return
Earnings day
-3.4%
Avg return
5 days after
+1.1%
Avg return
30 days after
32%
20 / 62 earnings
Positive
+23.5%
Q4 2017
Best reaction
-46.9%
Q4 2014
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +4.7% | -7.0% | — | |
| Q3 2025 | -18.6% | +3.9% | -7.8% | |
| Q2 2025 | +0.0% | +14.0% | +118.6% | |
| Q1 2025 | -3.9% | +2.0% | -3.9% | |
| Q4 2024 | +6.0% | +2.0% | +2.0% | |
| Q3 2024 | -2.2% | -25.3% | -28.6% | |
| Q2 2024 | -5.5% | +2.2% | -1.1% | |
| Q1 2024 | -1.0% | +4.9% | -4.9% | |
| Q4 2025 | +0.0% | -1.9% | +1.9% | |
| Q4 2023 | +1.6% | -12.0% | -4.0% | |
| Q3 2023 | -9.7% | -11.5% | +40.4% | |
| Q2 2023 | -7.4% | -18.9% | -8.4% | |
| Q1 2023 | +14.5% | +14.5% | +79.7% | |
| Q4 2022 | -8.3% | -16.7% | -6.9% | |
| Q3 2022 | +22.3% | +16.0% | +22.3% | |
| Q2 2022 | +12.5% | +33.3% | +16.7% | |
| Q1 2022 | +4.8% | +23.8% | -4.8% | |
| Q4 2021 | -22.7% | -29.5% | -38.6% | |
| Q3 2021 | -10.1% | -8.9% | -34.2% | |
| Q2 2021 | -20.5% | -10.3% | -12.8% | |
| Q1 2021 | +11.2% | +9.6% | +18.3% | |
| Q4 2020 | -16.2% | -21.6% | -97.0% | |
| Q3 2020 | -20.8% | -21.3% | -16.9% | |
| Q2 2020 | -7.6% | -0.8% | -12.9% | |
| Q1 2020 | -1.3% | -9.7% | -11.0% | |
| Q4 2019 | -7.8% | -18.4% | +25.2% | |
| Q3 2019 | -1.5% | -12.3% | -7.9% | |
| Q2 2019 | -5.8% | -7.4% | -4.1% | |
| Q1 2019 | -10.7% | -10.1% | -34.8% | |
| Q4 2018 | -9.4% | -14.4% | -4.4% | |
| Q3 2018 | +2.9% | -14.5% | -18.8% | |
| Q2 2018 | +5.7% | +7.5% | +17.0% | |
| Q1 2018 | +0.0% | +2.0% | +48.0% | |
| Q4 2017 | +23.5% | +26.5% | +29.4% | |
| Q3 2017 | +1.5% | -5.1% | +7.7% | |
| Q2 2017 | -24.4% | -25.6% | -15.4% | |
| Q1 2017 | -3.7% | -7.4% | -16.7% | |
| Q4 2016 | +11.5% | +3.3% | +3.3% | |
| Q3 2016 | -3.6% | -7.1% | +1.8% | |
| Q2 2016 | +19.8% | +17.8% | +5.9% | |
| Q1 2016 | -6.2% | — | — | |
| Q4 2015 | -8.7% | — | — | |
| Q3 2015 | +13.5% | — | — | |
| Q2 2015 | +8.0% | — | — | |
| Q1 2015 | -24.6% | — | — | |
| Q4 2014 | -46.9% | — | — | |
| Q3 2014 | +14.7% | — | — | |
| Q2 2014 | -5.1% | — | — | |
| Q1 2014 | -5.6% | — | — | |
| Q4 2013 | +7.0% | — | — | |
| Q3 2013 | -0.4% | — | — | |
| Q2 2013 | -12.9% | — | — | |
| Q1 2013 | -3.6% | — | — | |
| Q4 2012 | -5.0% | — | — | |
| Q3 2012 | -5.8% | — | — | |
| Q2 2012 | -2.3% | — | — | |
| Q1 2012 | +0.0% | — | — | |
| Q4 2011 | -5.9% | — | — | |
| Q3 2011 | -0.7% | — | — | |
| Q2 2011 | +2.8% | — | — | |
| Q1 2011 | +5.1% | — | — | |
| Q4 2010 | -3.1% | — | — | |
| Q3 2010 | — | — | — | |
| Q2 2010 | — | — | — | |
| Q1 2010 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro